Resultado de búsqueda
4 de jun. de 2023 · In a single-center pilot trial of neoadjuvant FOLFOX in which administration of chemoradiotherapy was reserved for patients whose tumors did not respond to chemotherapy, we found favorable ...
7 de jun. de 2023 · It improves disease-free survival (DFS) by decreasing pelvic recurrence but has short- and long-term toxicity. The PROSPECT trial compares FOLFOX chemotherapy with selective use of 5FUCRT (intervention) to 5FUCRT (control) for neoadjuvant treatment prior to TME for LARC.
27 de jul. de 2023 · In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival. (Funded by the National Cancer Institute; PROSPECT ClinicalTrials.gov number, NCT01515787.).
4 de jun. de 2023 · Neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) was noninferior to 5-FU CRT in participants with locally advanced rectal cancer. The 2 strategies achieved nearly identical disease-free survival outcomes, and at 5 years, the overall survival rates were similar.
25 de oct. de 2023 · To the Editor: I congratulate Schrag et al. (July 27 issue) 1 for successful completion of the PROSPECT trial (Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with...
4 de jun. de 2023 · PROSPECT was a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX versus 5FUCRT, which enrolled adults with rectal cancer clinically staged as T2N+, cT3N–, or cT3N+ who were candidates for sphincter-sparing surgery.
23 de ago. de 2023 · The PROSPECT trial compared induction chemotherapy with selective chemoradiation for patients with low-risk, mid-to-high rectal cancer. The results showed that chemoradiation could be omitted without compromising disease-free survival, local recurrence, or overall survival.
